Table 1 Clinical and pathological characteristics of patients in the training and validation cohorts
| Â | Total (N= 188) No.(%) | Training cohort (n=132) No.(%) | Validation cohort (n=56) No.(%) | P value |
|---|---|---|---|---|
Age | Â | Â | Â | 0.87 |
<62 | 89(47.3%) | 63(47.7%) | 26(46.4%) | Â |
≥62 | 99(52.7%) | 69(52.3%) | 30(53.6%) |  |
Stage | Â | Â | Â | 0.71 |
I-II | 94(50.0%) | 66(50.0%) | 28(50.0%) | Â |
III-IV | 94(50.0%) | 66(50.0%) | 28(50.0%) | Â |
SCC_Ag | Â | Â | Â | 0.21 |
<27.0 | 140(74.5%) | 102(77.3%) | 38(67.9%) | Â |
≥27.0 | 48(25.5%) | 30(22.7%) | 18(32.1%) |  |
Pelvic LNM | Â | Â | Â | 0.16 |
Yes | 81(43.1%) | 61(46.2%) | 20(35.7%) | Â |
No | 107(56.9%) | 71(53.8%) | 36(64.3%) | Â |
NLR_ change | Â | Â | Â | 0.62 |
<0.4 | 73(38.8%) | 56(42.4%) | 17(30.3%) | Â |
≥0.4 | 115(61.2%) | 76(57.6%) | 39(69.6%) |  |
PLR_ change | Â | Â | Â | 0.99 |
<2.1 | 147(78.2%) | 105(79.5%) | 42(75.0%) | Â |
≥2.1 | 41(21.8%) | 27(20.4%) | 14(25.0%) |  |
MLR_ change | Â | Â | Â | 0.11 |
<0.3 | 45(23.9%) | 32(24.2%) | 13(23.2%) | Â |
≥0.3 | 143(76.1%) | 100(75.8%) | 43(76.8%) |  |
SII_ change | Â | Â | Â | 0.50 |
<2.6 | 118(62.8%) | 82(62.1%) | 36(64.3%) | Â |
≥2.6 | 70(37.2%) | 50(37.9%) | 20(35.7%) |  |
ELR_ change | Â | Â | Â | 0.68 |
<0.1 | 35( 18.6%) | 27(20.5%) | 8( 14.3%) | Â |
≥0.1 | 153(81.4%) | 105(79.5%) | 48(85.7%) |  |
HALP_ pre | Â | Â | Â | 0.99 |
<30.8 | 82(43.6%) | 57(43.2%) | 25(44.6%) | Â |
≥30.8 | 106(56.4%) | 75(56.8%) | 31(55.4%) |  |
FNI_ pre | Â | Â | Â | 0.99 |
<44.7 | 91(48.4%) | 53(47.0%) | 29(51.8%) | Â |
≥44.7 | 97((51.6%) | 79(53.0%) | 27(48.2%) |  |
Clinical endpoints | Â | Â | Â | 0.11 |
None | 153(81.4%) | 108(81.8%) | 45(69.2%) | Â |
Recurrence or distant metastasis | 35( 18.6%) | 24( 18.2%) | 11(30.8%) | Â |